Skip to main navigation

Investor Relations

Company Statements Media Contact Email Alerts

Events & Presentations Financials Stock Information Governance Resources

Compliance & Transparency

Our Locations Medical Information

magnifying glass icon

Main Nav

Our Company
What We Do
Culture & Careers
Patient Resources
HCP Resources
Our Stories
Responsibility

Our Company
What We Do
Culture & Careers
Patient Resources
HCP Resources
Our Stories
Responsibility

Main Nav

Our Company
What We Do
Culture & Careers
Patient Resources
HCP Resources
Our Stories
News
Investors
Responsibility
Contact Us
United States

Home > Investors > events > event details > FDA Approval Call for Opzelura in Vitiligo

Incyte International Locations

NORTH AMERICA— HEADQUARTERS

EUROPE— HEADQUARTERS

THE NETHERLANDS

Close

Event Details

Events
Corporate Presentations
Scientific Presentations

FDA Approval Call for Opzelura in Vitiligo

Jul 19, 2022 at 8:00 AM EDT

Click here for Webcast

Supporting Materials

Presentation 4.8 MB

Investor Contacts

Ben Strain

Head of Investor Relations

© 2012-2024 Incyte.

Legal Notice
Suppliers
Site Map

Privacy Policy
Cookie Policy
Consumer Health Data Privacy Policy